depression

While a randomized-controlled trial is underway, Genomind hopes data from a new case-control study will convince insurers its PGx test can reduce healthcare utilization costs.

The company presented new data on the PGx test this week and expressed confidence that they can secure broader payor coverage for it.

The company launched the RxMatch Antidepressant Panel as the first step to grow beyond precision oncology and offer genomic assays for a wider range of diseases.

The company has recently launched its first diagnostic test on the market and is developing a second, which is currently in clinical trials.